Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Inactive · Last trade price
on Feb 16, 2024
Icosavax Revenue
In the year 2022, Icosavax had annual revenue of $582.00K, down -92.54%.
Revenue (ttm)
$582.00K
Revenue Growth
-92.54%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
766.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 582.00K | -7.22M | -92.54% |
Dec 31, 2021 | 7.80M | 6.19M | 382.80% |
Dec 31, 2020 | 1.62M | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionICVX News
- 11 months ago - ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX - PRNewsWire
- 1 year ago - ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX - Business Wire
- 1 year ago - SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders? - Business Wire
- 1 year ago - Why AstraZeneca Is Buying Icosavax For $1.1 Billion - Investopedia
- 1 year ago - AstraZeneca will pay up to $1.1B to acquire Icosavax, a Univ. of Washington biotech spinout - GeekWire
- 1 year ago - This Vaccine Stock Soars 46% After $1.1 Billion AstraZeneca Deal - Barrons
- 1 year ago - AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data - Business Wire
- 1 year ago - AstraZeneca Will Acquire RSV Vaccine Developer Icosavax For $1.1 Billion - Forbes